 |
 |
 |
 |
 |
 |
 |
|
|
 |
  |
 |
 |
 |
 |
 |
 |
| New Releases |
 |
Ridge Diagnostics, Inc. CEO to speak at Neurotech Investing and Partnering Conference
San Diego, CA May 5, 2011 –Ridge Diagnostics, Inc., a neurodiagnostic company, announced that Lonna J. Williams, CEO will speak at the 6th Annual Neurotech Investing and Partnering Conference to be held in San Francisco, CA at the St. Regis Hotel on May 9th and 10th.
Ridge Diagnostics will present Clinical Data on Blood Test for Depression at the American Psychiatric Association Annual Meeting
San Diego, CA April 5, 2011 –Ridge Diagnostics, Inc., a neurodiagnostic company, announced that the Scientific Program Committee of the American Psychiatric Association has accepted for presentation their scientific and clinical report entitled, “Assessment of a Biomarker Panel for Major Depressive Disorder in a Community Based Study”.
Ridge Diagnostics Presents Clinical Data on Blood Test for Depression at U.S. Psychiatric and Mental Health Congress
San Diego, CA November 18, 2010 — Ridge Diagnostics, Inc., a neurodiagnostic company, announced that data from a Clinical Experience Program for its first-in-class, proprietary blood test for Major Depressive Disorder (MDD) will be presented during a poster session entitled Clinician Acceptance and Utility of a Multianalyte Biomarker Panel for Major Depressive Disorder (MDD) Diagnosis.
CONNECT Announces Finalists For 22nd Annual Most Innovative New Product Awards
September 28, 2009 SAN DIEGO - CONNECT, regarded as the world's most successful regional program
linking inventors and entrepreneurs with the resources they need for success, today
announced the finalists for the 2009 Most Innovative New Product (MIP) Awards. Winners
will be announced on December 11th at the MIP Awards Luncheon, held at the Hilton La
Jolla Torrey Pines, to an audience of over 800 of San Diego's top executives,
entrepreneurs, service providers and academics.
Ridge Diagnostics Wins Growth-Promoting Loan from Biotech Center
RESEARCH TRIANGLE PARK, N.C. July 10, 2009 — Ridge Diagnostics, Inc., a neurodiagnostic company with a first-in-class, proprietary blood test for Major Depressive Disorder (MDD), announced the award of a $202,500 loan from the North Carolina Biotechnology Center. The funds will further develop the company’s CLIA-certified laboratory in Research Triangle Park, thereby supporting the commercialization of its proprietary blood test for depression.
Ridge Presents Clinical Data on Blood Test for Depression At American Psychiatric Association Annual Meeting May 20, 2009 –Ridge Diagnostics announced that data from clinical studies for its proprietary blood test for depression, will be presented during a poster session entitled Multianalyte Biomarker Blood Test to Aid in Diagnosis, Treatment and Management of Major Depressive Disorder, at the American Psychiatric Association Annual Meeting, May 20, 2009.
The poster will be presented by Dr. Perry Renshaw, Chief Medical Officer of
Ridge Diagnostics and Director of Magnetic Resonance, Utah Brain Institute, and Professor of Psychiatry,
University of Utah School of Medicine Ridge Diagnostics Awarded Phase 2 National Science Foundation Grant - Grant Supports First Blood Test for Depression
San Diego, CA April 24, 2009 –Ridge Diagnostics, Inc.,
a neurodiagnostic company commercializing its first-in-class, proprietary blood
test for depression or Major Depressive Disorder(MDD), has been awarded a Phase 2,
National Science Foundation, Small Business Innovation Research
(SBIR) Program The grant will be used to further the clinical development and
commercialization of its blood test for depression, the first blood test for
any neuropsychiatric disorder. Health Buzz: Depression Hikes Heart Failure Risk
April 14, 2009, U.S News and World Report - new
study suggests that depression may hurt the heart. It found that people
with heart disease caused by blockage of coronary arteries
face an increased risk of heart failure if they become depressed, according to HealthDay. And
it was a risk that didn't seem to be curtailed by antidepressants. The
finding wasn't surprising, said the report, since research has previously
indicated that depression may up the risk of
heart failure
in people without heart disease. Recently, U.S. News wrote about a
new recommendation from health experts that all primary-care doctors
screen their teenage patients for
depression, a risk factor for suicide. Other reports have covered how depression affects
the immune system and how it can manifest in the elderly.
Ridge Announces First Blood Test for Major Depressive Disorder -Establishes CLIA Laboratory to Offer Depression Diagnostic Test San Diego, CA, April 7, 2009 – Ridge Diagnostics, Inc., is a San Diego based neurodiagnostic Company which in January 2009 opened their CLIA certified laboratory and began testing services for its first-in-class blood test for depression (Major Depressive Disorder). This unique blood test will aid psychiatrists and primary care physicians in the diagnosis and management of this complex condition. “We are extremely pleased to announce the clinical availability of this important tool to aid in the diagnosis and management of depression. This is the first time a blood test has been shown effective in clinical studies for diagnosing and monitoring patients with this disorder. The test provides the long awaited proof of a biological basis for this neuropsychiatric condition,” stated Lonna J. Williams, Chief Commercial Officer. “Psychiatrists across the country have told us that up to 30% of their patients are difficult to manage or are non-compliant with treatment. This test provides evidence that depression is a psychological condition expressed by biological changes. Physicians believe it will improve the acceptance of the diagnosis and yield a higher level of treatment”.
Over 20 million patients are treated for depression each year in the
Ridge Diagnostics, Inc.
Announces Appointment of Stan
Sewitch as President and Chief Executive Officer
San Diego, CA
March 2, 2009 – Ridge Diagnostics, Inc.--
a neurodiagnostic Company
commercializing a
first in class, proprietary blood test for Major Depressive Disorder,
has announced its Board of Directors’ decision to appoint Stan Sewitch, a
member of the Board of Directors, as President and Chief Executive Officer. “We are pleased to announce that Stan Sewitch, a seasoned corporate executive with successful entrepreneurial experience, has accepted the position of President and CEO of Ridge Diagnostics” stated Larry G. Stambaugh, Chairman. “Stan’s leadership and experience in early stage companies will be essential to support the growth of this exciting new company”. Mr.
Sewitch is also the head of KI Investment Holdings, LLC, a private equity
company who led the seed financing for the company.
Stan was also the founder and CEO of HRG, Inc. an organizational,
operational, human resources and strategic consulting company, acquired by
RSM McGladrey. Stan formed two
other companies, Emlyn Systems, a software company publishing a human
resources information system, and Chromagen, a biotechnology company
endeavoring to commercialize proprietary assays for drug research. Stan held
senior management positions in operations and human resources at several
companies including TRW's LSI products division in
Precision Human Biolaboratory Changes Name to Ridge Diagnostics, Inc.
-Company Prepares for Commercialization
San Diego, CA November 4,
2008 – Precision Human Biolaboratory (PHB)-- a neurodiagnostic
company developing a first in class,
proprietary blood test for Major Depressive Disorder, has
announced the Board of Directors decision to change the name from PHB to
Ridge Diagnostics, Inc. “We
are pleased to announce the Company has reached the critical point in our
growth where we are prepared to move forward with our commercial strategy”,
stated Lonna J. Williams, Chief Commercial Officer .
“Changing our name to Ridge Diagnostics is the first step toward
introducing the Company and its unique proprietary products to the market”. Ridge
was founded in 2006 and gained initial funding through a prestigious
National Science Foundation award.
Because of its promising technology and successful clinical study, the
Company was also granted funding through the
Precision
Human Biosciences Receives
San Diego, CA November 20, 2007— Precision Human
Biolaboratory (PHB),
a neurodiagnostic Company developing a first in class, proprietary blood
test for Major Depressive Disorder,
announced the
PHB, founded in 2006, is developing a new and
unique, proprietary technique for diagnosing and monitoring the therapy of
clinical depression, a debilitating condition referred to as major
depressive disorder (MDD). Physicians
traditionally diagnose and monitor MDD with subjective behavioral
questionnaires and a clinical assessment.
Five experienced life science professionals,
including Dr. Yiwu He, who serves as President, and Dr. John Bilello, Chief
Scientific Officer, founded the company. Previously,
Dr. He was the global head of GlaxoSmithKline's
PHB has filed a number of
Precision Human Biosciences Awarded National Science Foundation Grant “We
are pleased to announce the National Science Foundation’s recognition of
Ridge’s technological accomplishments.
This prestigious grant will enable us to further our work toward a
marketable product,” stated Larry G. Stambaugh, Chairman of Ridge. This
project, under the direction of Dr. John Bilello, Chief Scientific Officer,
is entitled “ SBIR: Phase I:
Molecular Interaction Measurement System:
A label-free Detection Platform”.
|